Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

On June 1, 2021 Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported abstracts and presentations by its collaborators for the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which will be held June 4-8, 2021 (Press release, Halozyme, JUN 1, 2021, View Source [SID1234583360]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Janssen Research & Development, LLC (Janssen)-sponsored study with therapeutics utilizing ENHANZE technology:

Subcutaneous daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis

Oral abstract session: Updated results from the Phase 3 ANDROMEDA study of DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of newly diagnosed AL amyloidosis (Abstract #8003).
Bristol Myers Squibb-sponsored study with therapeutics utilizing ENHANZE technology:

CheckMate 8KX: Phase 1/2 multi-tumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20)

Poster session: The first data on the pharmacokinetics (PK), safety, tolerability, and pharmacodynamics (PD) of subcutaneous nivolumab + rHuPH20 (Abstract #2575).
Roche-sponsored study with therapeutics utilizing ENHANZE technology:

Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States

Poster session: The aim of this study is to estimate the incremental difference in non-drug costs between PH FDC SC and PT IV for a typical patient receiving treatment for HER2-positive early breast cancer in Western Europe and the United States (Abstract #544).